首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1316263

全球輔助生殖技術市場 - 2023-2030 年

Global Assisted Reproductive Technology Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

2022 年，全球輔助生殖技術市場規模達到338 億美元，預計到2030 年將實現利潤豐厚的成長，達到537 億美元。在預測期內（2023-2030 年），全球輔助生殖技術市場的複合年成長率預計將達到6.1%。

輔助生殖技術（ART）推動了生殖醫學的發展，提高了生育治療的成功率、安全性和效率。持續的研究和技術發展有助於更好地了解和管理不孕不育症。因此，該領域不斷發展，為尋求生殖援助的個人和夫婦提供了創新的解決方案和治療方案。

市場動態

主要企業的關鍵戰略有助於推動市場成長

主要企業的關鍵戰略有助於推動市場成長。例如，2021 年1 月5 日，著名的婦女保健解決方案提供商CooperSurgical 收購了為診所和患者提供冷凍儲存軟體的知名供應商Embryo Options。通過此次收購，CooperSurgical 的全套突破性生殖療法得到了擴展。

與Embryo Options 合作的診所將受益於低溫保存的胚胎、卵子和精子的自動計費和簡化管理，從而增加採集量、降低標本遺棄率和低溫庫存管理成本。

單親家庭數量增加將推動市場成長

在整個預測期內，單親家庭數量的不斷增加，以及人們對同性婚禮和輔助生殖技術認知的提高，都可能對ART 市場的成長產生重要影響。

例如，根據人權運動（HRC）基金會2022 年的報告，2022 年，同性婚姻合法的國家數量已攀升至32 個，一些國家的議會或法院程序已經啟動，預計這一數位還將進一步上升。由於同性婚姻的增加，對ART 治療的需求預計將急劇上升，從而促進該行業的成長。

輔助生殖技術系統的高成本將阻礙市場成長

ART 程序涉及實驗室工作，包括精子和卵子檢索、受精、胚胎培養和冷凍保存。這些實驗室服務所需的專業設備、耗材和專業知識都會增加成本。此外，長期儲存冷凍胚胎或配子也會產生持續的維護和儲存設施費用。

ART 技術和科技的進步需要不斷的研發。在生殖醫學領域進行研究、臨床試驗和創新的成本反映在ART 系統的總支出中。

COVID-19 影響分析

大流行期間，由於封鎖、社會隔離措施和醫療系統不堪重負，許多抗逆轉錄病毒療法診所不得不暫時中止或限制服務。這種干擾導致個人和夫婦的生育治療推遲或取消，造成了巨大的情感和後勤挑戰。

大流行使個人難以進行生育評估和診斷檢測。非必要的醫療預約和程序往往被推遲或取消，導致確定和解決生育問題的延誤。診斷和治療的延誤進一步延長了許多個人和夫婦的生育之路。

俄烏戰爭影響分析

據估計，俄烏衝突對全球輔助生殖技術市場的影響不大，原因是該地區的主要市場參與者較少。不過，在預測期內，原料進出口的影響預計對全球輔助生殖技術市場的成長影響不大。

人工智慧的影響分析

人工智慧可與胚胎植入前基因檢測（PGT）結合使用，分析胚胎的基因和染色體數據。人工智慧算法可以識別特定遺傳標記與胚胎存活率之間的模式和相關性，幫助預測成功植入的可能性，降低後代患遺傳疾病的風險。值得注意的是，雖然人工智慧在改善ART 系統方面具有巨大潛力，但在使用時應始終結合醫療保健專業人員的專業知識和指導。

Market Overview

The global assisted reproductive technology market reached US$ 33.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 53.7 billion by 2030. The global assisted reproductive technology market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030).

Assisted Reproductive Technology (ART) drives advancements in reproductive medicine, leading to improved success rates, safety, and efficiency of fertility treatments. Ongoing research and technological developments contribute to better understanding and management of infertility. As a result, the field continues to evolve, offering innovative solutions and treatment options to individuals and couples seeking reproductive assistance.

Market Dynamics

The Key Strategies by the Key Players Helps to Drive Market Growth

The key strategies by the key players helps to drive market growth. For instance, on January 5, 2021, CooperSurgical, a prominent provider of women's health care solutions, has acquired Embryo Options, a well-known provider of cryo-storage software for clinics and patients. CooperSurgical's full array of breakthrough reproductive treatments has been expanded with this acquisition.

Clinics that work with Embryo Options benefit from automated billing and streamlined management of cryo-preserved embryos, eggs, and sperm, which leads to increased collections, lower specimen abandonment, and lower cryo-inventory management costs.

The Rising Number of Single Parenting will Drive the Market Growth

The growing number of single parents, as well as increased awareness of same-sex weddings and assisted reproductive technologies, are likely to play a key influence in the growth of the ART market throughout the forecast period.

For instance, according to the Human Rights Campaign (HRC) Foundation's 2022 report, the number of nations where same-sex marriage is legal has climbed to 32 in 2022, with parliamentary or court processes beginning in several countries, and this graph is anticipated to rise further. As a result of the increase in same-sex marriages, demand for ART treatments is predicted to rise dramatically, boosting growth in the maket.

High Cost of Assisted Reproductive Technology Systems will Hamper the Market Growth

ART procedures involve laboratory work, including sperm and egg retrieval, fertilization, embryo culture, and cryopreservation. The specialized equipment, consumables, and expertise required for these laboratory services contribute to the cost. Additionally, long-term storage of frozen embryos or gametes incurs ongoing fees for maintenance and storage facilities.

Advancements in ART techniques and technologies require ongoing research and development. The cost of conducting research studies, clinical trials, and innovation in the field of reproductive medicine is reflected in the overall expense of ART systems.

COVID-19 Impact Analysis

Many ART clinics had to temporarily suspend or limit their services during the pandemic due to lockdowns, social distancing measures, and overwhelmed healthcare systems. This disruption led to the postponement or cancellation of fertility treatments for individuals and couples, causing significant emotional and logistical challenges.

The pandemic made it difficult for individuals to undergo fertility evaluations and diagnostic tests. Non-essential medical appointments and procedures were often postponed or canceled, leading to delays in identifying and addressing fertility issues. This delay in diagnosis and treatment further prolonged the journey to parenthood for many individuals and couples.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global assisted reproductive technology market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global assisted reproductive technology market growth over the forecast period.

Artificial Intelligence Impact Analysis

AI can be used in conjunction with preimplantation genetic testing (PGT) to analyze genetic and chromosomal data from embryos. AI algorithms can identify patterns and correlations between specific genetic markers and embryo viability, helping predict the likelihood of successful implantation and reducing the risk of genetic disorders in offspring. It is important to note that while AI holds great potential in improving ART systems, it should always be used in conjunction with the expertise and guidance of healthcare professionals.

Segment Analysis

The global assisted reproductive technology market is segmented based on technology type, procedure, end user and region.

The In-Vitro Fertilization Accounted for Approximately 53.2% of the Assisted Reproductive Technology Market Share

The ultimate benefit of IVF is a successful pregnancy and a healthy baby. IVF can make this a reality for people who might otherwise be unable to conceive a child. IVF gives women with blocked or damaged fallopian tubes the best chance of producing a child using their own eggs. Furthermore, new product releases and approvals by companies contribute to the segment's growth.

For instance, October. 25, 2022, TMRW Life Sciences, Inc. (TMRW), the company that invented of the world's first automated specimen management platform for frozen eggs and embryos used in in vitro fertilisation (IVF), has announced the opening of the world's most advanced fertility specimen cryostorage facility.

This technologically advanced facility in New York provides a new standard of care directly to patients and fertility clinic partners for the first time, delivering unparalleled levels of transparency into the safety of frozen eggs and embryos at the heart of practically every IVF experience. As a result, the aforementioned elements contribute to segment growth.

Geographical Analysis

North America Accounted for Approximately 43.4% of the Market Share

North America is expected to hold a significant market share in the global assisted reproductive technology market over the forecast period, owing to factors such as rising infertility in the region and public-sector initiatives that are expected to boost market growth over the forecast period.

For instance, infertility is on the rise. Infertile couples are using assisted reproductive technology (ART) at a rate of 5% to 10% each year. According to the United Nations, there were five children for every woman in the globe in 1950. In 2020, there will be two children for every woman on the planet.

In the United States, there has been a long-term reduction in birth and fertility rates, which has been linked to a variety of causes such as women's increased education and professional options, later marriage, improved access to contraception, delayed childbirth, and smaller family size. As a result, infertility rates are rising, which aids regional growth.

Competitive Landscape

The major global players in the assisted reproductive technology market are: Irvine Scientific (FUJIFILM Corporation), CooperSurgical Inc, Thermo Fisher Scientific, Inc., Genea Biomedx, Microm UK Ltd, Hamilton Thorne Inc, Merck KGaA, Laboratoire CCD, Vitrolife AB, OvaScience Inc among others.

Why Purchase the Report?

To visualize the global assisted reproductive technology market segmentation based on technology type, procedure, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of assisted reproductive technology market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global assisted reproductive technology market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology Type
3.2. Snippet by Procedure
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The constant rise in the infertility rate
  - 4.1.1.2. Improving ART success rates
- 4.1.2. Restraints
  - 4.1.2.1. High cost of assisted reproductive technology systems
- 4.1.3. Opportunity
  - 4.1.3.1. ART allows individuals and couples to have greater control over their reproductive choices
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Technology Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 7.1.2. Market Attractiveness Index, By Technology Type
7.2. In Vitro-fertilization (IVF) *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Artificial Insemination (AI-IUI)
7.4. Frozen Embryo Replacement (FER)
7.5. Others

8. By Procedure

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 8.1.2. Market Attractiveness Index, By Procedure
8.2. Fresh donor *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Fresh non-donor
8.4. Frozen donor
8.5. Frozen non-donor
8.6. Embryo banking

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospital *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Fertility Clinics
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Plan Type
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Irvine Scientific (FUJIFILM Corporation) *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. CooperSurgical Inc
12.3. Thermo Fisher Scientific, Inc.
12.4. Genea Biomedx
12.5. Microm UK Ltd
12.6. Hamilton Thorne Inc
12.7. Merck KGaA
12.8. Laboratoire CCD
12.9. Vitrolife AB
12.10. OvaScience Inc.

LIST NOT EXHAUSTIVE